An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Ja0005 50646, Calgary, Canada

Ja0005 50644, Montreal, Canada

Ja0005 50645, Saskatoon, Canada

Ja0005 40777, Indre-et-Loire, France

Ja0005 40510, Le Kremlin-Bicêtre, France

Ja0005 40778, Paris, France

Ja0005 40776, Poitiers, France

Ja0005 40369, Berlin, Germany

Ja0005 40356, Dresden, Germany

Ja0005 40072, Freiburg im Breisgau, Germany

Ja0005 40852, Hamburg, Germany

Ja0005 40787, Sankt Augustin, Germany

Ja0005 40779, Sendenhorst, Germany

Ja0005 40427, Tübingen, Germany

Ja0005 40720, Krakow, Poland

Ja0005 40780, Sosnowiec, Poland

Ja0005 40781, Esplugues de Llobregat, Spain

Ja0005 40100, Madrid, Spain

Ja0005 40782, Valencia, Spain

Ja0005 40786, Bristol, United Kingdom

Ja0005 40783, Manchester, United Kingdom

Ja0005 40785, Nottingham, United Kingdom

Ja0005 40784, Stroke-on-trent, United Kingdom